%0 Generic
%A Szabados, B. E.
%A Rodriguez-Vida, A.
%A Duran, I.
%A Crabb, S. J.
%A van-der-Heijden, M. S.
%A Pous, A. Font
%A Gravis, G.
%A Herranz, U. Anido
%A Protheroe, A.
%A Ravaud, A.
%A Maillet, D.
%A Mendez, M. J.
%A Suarez, C.
%A Linch, M.
%A Prendergast, A.
%A Tyson, C.
%A Mousa, K.
%A Castellano, D.
%A Powles, T. B.
%T A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis
%D 2020
%@ 0923-7534
%U https://hdl.handle.net/10668/25477
%X Background. ABACUS is a phase II single-arm study that evaluated the safety and efficacy of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) awaiting radical cystectomy (RC).Methods. This single arm, phase II study investigated two cycles of atezolizumab (1200mg given every 3 weeks) prior to RC in MIBC(T2-4aN0M0) (NCT02662309). The study included patients who were ineligible or refused neoadjuvant cisplatin-based chemotherapy and had transitional cell histology. Pathological complete response (pCR) was the primary endpoint. Adverse events (AEs) and surgical complications were assessed using CTCAE v4.03 and the Clavien-Dindo classification.
%K Cisplatin
%K atezolizumab
%K Urinary Bladder Neoplasms
%K Muscles
%~